A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.

Treatment with single-agent chloroquine 500 mg daily in the preoperative setting was not associated with any significant effects on breast cancer cellular proliferation. It was, however, associated with toxicity that may affect its broader use in oncology.